S&P 500   4,538.28 (+0.41%)
DOW   35,623.69 (+0.47%)
QQQ   374.77 (-0.19%)
AAPL   148.80 (+0.03%)
MSFT   307.22 (-0.33%)
FB   340.78 (+0.23%)
GOOGL   2,838.69 (-0.91%)
TSLA   865.86 (+0.18%)
AMZN   3,416.70 (-0.80%)
NVDA   220.62 (-1.02%)
BABA   177.69 (+0.39%)
NIO   39.73 (-0.75%)
CGC   14.13 (-1.46%)
GE   105.34 (+0.58%)
AMD   116.32 (+-0.01%)
MU   68.39 (+1.21%)
T   25.95 (+1.41%)
F   15.89 (+3.05%)
ACB   7.56 (+1.48%)
DIS   170.62 (-0.33%)
PFE   42.84 (+1.78%)
BA   216.60 (+0.29%)
AMC   40.82 (+0.05%)
S&P 500   4,538.28 (+0.41%)
DOW   35,623.69 (+0.47%)
QQQ   374.77 (-0.19%)
AAPL   148.80 (+0.03%)
MSFT   307.22 (-0.33%)
FB   340.78 (+0.23%)
GOOGL   2,838.69 (-0.91%)
TSLA   865.86 (+0.18%)
AMZN   3,416.70 (-0.80%)
NVDA   220.62 (-1.02%)
BABA   177.69 (+0.39%)
NIO   39.73 (-0.75%)
CGC   14.13 (-1.46%)
GE   105.34 (+0.58%)
AMD   116.32 (+-0.01%)
MU   68.39 (+1.21%)
T   25.95 (+1.41%)
F   15.89 (+3.05%)
ACB   7.56 (+1.48%)
DIS   170.62 (-0.33%)
PFE   42.84 (+1.78%)
BA   216.60 (+0.29%)
AMC   40.82 (+0.05%)
S&P 500   4,538.28 (+0.41%)
DOW   35,623.69 (+0.47%)
QQQ   374.77 (-0.19%)
AAPL   148.80 (+0.03%)
MSFT   307.22 (-0.33%)
FB   340.78 (+0.23%)
GOOGL   2,838.69 (-0.91%)
TSLA   865.86 (+0.18%)
AMZN   3,416.70 (-0.80%)
NVDA   220.62 (-1.02%)
BABA   177.69 (+0.39%)
NIO   39.73 (-0.75%)
CGC   14.13 (-1.46%)
GE   105.34 (+0.58%)
AMD   116.32 (+-0.01%)
MU   68.39 (+1.21%)
T   25.95 (+1.41%)
F   15.89 (+3.05%)
ACB   7.56 (+1.48%)
DIS   170.62 (-0.33%)
PFE   42.84 (+1.78%)
BA   216.60 (+0.29%)
AMC   40.82 (+0.05%)
S&P 500   4,538.28 (+0.41%)
DOW   35,623.69 (+0.47%)
QQQ   374.77 (-0.19%)
AAPL   148.80 (+0.03%)
MSFT   307.22 (-0.33%)
FB   340.78 (+0.23%)
GOOGL   2,838.69 (-0.91%)
TSLA   865.86 (+0.18%)
AMZN   3,416.70 (-0.80%)
NVDA   220.62 (-1.02%)
BABA   177.69 (+0.39%)
NIO   39.73 (-0.75%)
CGC   14.13 (-1.46%)
GE   105.34 (+0.58%)
AMD   116.32 (+-0.01%)
MU   68.39 (+1.21%)
T   25.95 (+1.41%)
F   15.89 (+3.05%)
ACB   7.56 (+1.48%)
DIS   170.62 (-0.33%)
PFE   42.84 (+1.78%)
BA   216.60 (+0.29%)
AMC   40.82 (+0.05%)
NASDAQ:BEAT

BioTelemetry Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$71.46
$72.27
52-Week Range N/A
VolumeN/A
Average Volume978,536 shs
Market Capitalization$2.47 billion
P/E Ratio153.11
Dividend YieldN/A
Beta1.35

Receive BEAT News and Ratings via Email

Sign-up to receive the latest news and ratings for BioTelemetry and its competitors with MarketBeat's FREE daily newsletter.


BioTelemetry logo

About BioTelemetry

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Specialty outpatient clinics, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BEAT
Employees
1,700
Year Founded
N/A

Sales & Book Value

Annual Sales
$439.11 million
Book Value
$10.83 per share

Profitability

Net Income
$29.84 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$2.47 billion
Next Earnings Date
N/A
Optionable
Optionable

MarketRank

Overall MarketRank

2.23 out of 5 stars

Medical Sector

319th out of 1,360 stocks

Specialty Outpatient Clinics, Not Elsewhere Classified Industry

1st out of 5 stocks

Analyst Opinion: 3.1Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -












BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions

Is BioTelemetry a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BioTelemetry stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAT, but not buy additional shares or sell existing shares.
View analyst ratings for BioTelemetry
or view top-rated stocks.

What stocks does MarketBeat like better than BioTelemetry?

Wall Street analysts have given BioTelemetry a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioTelemetry wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were BioTelemetry's earnings last quarter?

BioTelemetry, Inc. (NASDAQ:BEAT) issued its earnings results on Thursday, October, 29th. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.38 by $0.07. The medical research company had revenue of $114.66 million for the quarter, compared to analyst estimates of $105.12 million. BioTelemetry had a net margin of 4.03% and a trailing twelve-month return on equity of 16.68%. BioTelemetry's revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.52 EPS.
View BioTelemetry's earnings history
.

What price target have analysts set for BEAT?

5 brokerages have issued 1 year target prices for BioTelemetry's stock. Their forecasts range from $52.00 to $72.00. On average, they expect BioTelemetry's share price to reach $62.67 in the next year.
View analysts' price targets for BioTelemetry
or view top-rated stocks among Wall Street analysts.

Who are BioTelemetry's key executives?

BioTelemetry's management team includes the following people:
  • Mr. Joseph H. Capper, CEO, Pres & Director (Age 57, Pay $1.21M)
  • Ms. Heather C. Getz, Exec. VP, CFO & Chief Admin. Officer (Age 46, Pay $616.68k)
  • Mr. Fred Broadway III, Pres of BioTel Heart (Age 51, Pay $524.63k)
  • Mr. Daniel M. Wisniewski, Sr. VP of Technical Operations (Age 57, Pay $506.54k)
  • Dr. Andrei G. Stoica, Chief Technology Officer
  • Cody Cowper, VP of Legal & Corp. Sec.
  • Amy M. Knapp, Vice president of Corp. Communications
  • Mr. Tim Raher, Sr. VP of HR
  • Dr. Peter R. Kowey, Medical Director and Chairman of Medical Advisory Board
  • Mr. Scott Satin, Pres & GM of BioTel Research

What is Joseph H. (Joe) Capper's approval rating as BioTelemetry's CEO?

40 employees have rated BioTelemetry CEO Joseph H. (Joe) Capper on Glassdoor.com. Joseph H. (Joe) Capper has an approval rating of 53% among BioTelemetry's employees. This puts Joseph H. (Joe) Capper in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of BioTelemetry's key competitors?

What other stocks do shareholders of BioTelemetry own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTelemetry investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), (CGC), Square (SQ), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA), Netflix (NFLX) and Gilead Sciences (GILD).

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How much money does BioTelemetry make?

BioTelemetry has a market capitalization of $0.00 and generates $439.11 million in revenue each year. The medical research company earns $29.84 million in net income (profit) each year or $1.95 on an earnings per share basis.

How many employees does BioTelemetry have?

BioTelemetry employs 1,700 workers across the globe.

What is BioTelemetry's official website?

The official website for BioTelemetry is www.gobio.com.

Where are BioTelemetry's headquarters?

BioTelemetry is headquartered at 1000 CEDAR HOLLOW ROAD, MALVERN PA, 19355.

How can I contact BioTelemetry?

BioTelemetry's mailing address is 1000 CEDAR HOLLOW ROAD, MALVERN PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected].


This page was last updated on 10/20/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.